Yevgeniy Gindin1, Anuj Gaggar1, Anna S Lok2, Harry L A Janssen3, Carlo Ferrari4, G Mani Subramanian1, Zhaoshi Jiang1, Henry Masur5, Benjamin Emmanuel6, Bhawna Poonia6, Shyam Kottilil6. 1. Gilead Sciences, Foster City, California, USA. 2. Division of Gastroenterology and Hepatology, University of Michigan Health System, Ann Arbor, Michigan, USA. 3. Toronto Centre for Liver Disease, Toronto General Hospital, University Health Network Sandra Rotman Centre for Global Health, University of Toronto, Toronto, Ontario, Canada. 4. Department of Infectious Diseases, University of Parma, Parma, Italy. 5. Critical Care Medicine Department, NIH Clinical Center, National Institutes of Health , Bethesda, Maryland, USA. 6. Division of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Abstract
BACKGROUND: Several chronic diseases accelerate biological aging. We investigated age acceleration and the association between peripheral blood DNA methylation (DNAm) and immune cell markers in patients chronically infected with the hepatitis B virus (HBV) or the hepatitis C virus (HCV) with and without human immunodeficiency virus (HIV) co-infection. METHODS: Age acceleration was measured as the difference between epigenetic age (Horvath clock) and chronological age. The immune marker model of age acceleration was developed using Elastic Net regression to select both the immune markers and their associated weights in the final linear model. RESULTS: Patients with chronic HBV (n = 51) had a significantly higher median epigenetic age compared to chronological age (age accelerated) (P < .001). In patients with chronic HCV infection (n = 63), age acceleration was associated with liver fibrosis as assessed by histology (P < .05), or presence of HIV co-infection (P < .05), but not HCV mono-infection. Age acceleration defined by immune markers was concordant with age acceleration by DNA methylation (correlation coefficient = .59 in HBV; P = .0025). One-year treatment of HBV patients with nucleoside therapy was associated with a modest reduction in age acceleration, as measured using the immune marker model (-.65 years, P = .018). CONCLUSION: Our findings suggest that patients with chronic viral hepatitis have accelerated epigenetic aging, that immune markers define biological age, and have the potential to assess the effects of therapeutic intervention on age acceleration.
BACKGROUND: Several chronic diseases accelerate biological aging. We investigated age acceleration and the association between peripheral blood DNA methylation (DNAm) and immune cell markers in patients chronically infected with the hepatitis B virus (HBV) or the hepatitis C virus (HCV) with and without human immunodeficiency virus (HIV) co-infection. METHODS: Age acceleration was measured as the difference between epigenetic age (Horvath clock) and chronological age. The immune marker model of age acceleration was developed using Elastic Net regression to select both the immune markers and their associated weights in the final linear model. RESULTS: Patients with chronic HBV (n = 51) had a significantly higher median epigenetic age compared to chronological age (age accelerated) (P < .001). In patients with chronic HCV infection (n = 63), age acceleration was associated with liver fibrosis as assessed by histology (P < .05), or presence of HIV co-infection (P < .05), but not HCV mono-infection. Age acceleration defined by immune markers was concordant with age acceleration by DNA methylation (correlation coefficient = .59 in HBV; P = .0025). One-year treatment of HBV patients with nucleoside therapy was associated with a modest reduction in age acceleration, as measured using the immune marker model (-.65 years, P = .018). CONCLUSION: Our findings suggest that patients with chronic viral hepatitis have accelerated epigenetic aging, that immune markers define biological age, and have the potential to assess the effects of therapeutic intervention on age acceleration.
Authors: Gregory M Lucas; Shruti H Mehta; Mohamed G Atta; Gregory D Kirk; Noya Galai; David Vlahov; Richard D Moore Journal: AIDS Date: 2007-11-30 Impact factor: 4.177
Authors: Anna S Lok; Calvin Q Pan; Steven-Huy B Han; Huy N Trinh; W Jeffrey Fessel; Timothy Rodell; Benedetta Massetto; Lanjia Lin; Anuj Gaggar; G Mani Subramanian; John G McHutchison; Carlo Ferrari; Hannah Lee; Stuart C Gordon; Edward J Gane Journal: J Hepatol Date: 2016-05-19 Impact factor: 25.083
Authors: Timothy J Triche; Daniel J Weisenberger; David Van Den Berg; Peter W Laird; Kimberly D Siegmund Journal: Nucleic Acids Res Date: 2013-03-09 Impact factor: 16.971
Authors: Ruth Pidsley; Chloe C Y Wong; Manuela Volta; Katie Lunnon; Jonathan Mill; Leonard C Schalkwyk Journal: BMC Genomics Date: 2013-05-01 Impact factor: 3.969
Authors: Ake T Lu; Austin Quach; James G Wilson; Alex P Reiner; Abraham Aviv; Kenneth Raj; Lifang Hou; Andrea A Baccarelli; Yun Li; James D Stewart; Eric A Whitsel; Themistocles L Assimes; Luigi Ferrucci; Steve Horvath Journal: Aging (Albany NY) Date: 2019-01-21 Impact factor: 5.682
Authors: Joseph Balnis; Andy Madrid; Kirk J Hogan; Lisa A Drake; Hau C Chieng; Anupama Tiwari; Catherine E Vincent; Amit Chopra; Peter A Vincent; Michael D Robek; Harold A Singer; Reid S Alisch; Ariel Jaitovich Journal: Clin Epigenetics Date: 2021-05-25 Impact factor: 6.551